To limit the risk of fire and reduce denitrogenation time to prevent decompression sickness to support frequent extravehicular activities on the Moon, a hypobaric (P B = 414 mmHg) and mildly hypoxic (ppO 2 = 132 mmHg, 32% O 2 -68% N 2 ) living environment is considered for the Crew Exploration Vehicle (CEV) and Lunar Surface Access Module (LSAM). With acute change in ppO2 from 145-178 mmHg at standard vehicular operating pressure to less than 125 mmHg at desired lunar surface vehicular operating pressures, there is the possibility that some crewmembers may develop symptoms of Acute Mountain Sickness (AMS). The signs and symptoms of AMS (headache plus nausea, dizziness, fatigue, or sleeplessness), could impact crew health and performance on lunar surface missions. Methods: An exhaustive literature review on the topic of the physiological effects of reduced ppO2 and absolute pressure as may contribute to the development of altitude symptoms or AMS. The results of the nine most rigorous studies were collated, analyzed and contents on AMS and hypoxia symptoms summarized. Results: There is evidence for an absolute pressure effect per se on AMS, so the higher the altitude for a given hypoxic alveolar O 2 partial pressure (P A O 2 ), the greater the AMS response. About 25% of adults are likely to experience mild AMS near 2,000 m altitude following a rapid ascent from sea level while breathing air (6,500 feet, acute P A O 2 = 75 mmHg). The operational experience with the Shuttle staged denitrogenation protocol at 528 mmHg (3,048 m) while breathing 26.5% O 2 (acute P A O 2 = 85 mmHg) in astronauts adapting to microgravity suggests a similar likely experience in the proposed CEV environment. Conclusions: We believe the risk of mild AMS is greater given a P A O 2 of 77 mmHg at 4,876 m altitude while breathing 32% O 2 than at 1,828 m altitude while breathing 21% O 2 . Only susceptible astronauts would develop mild and transient AMS with prolonged exposure to 414 mmHg (4,876 m) while breathing 32% O 2 (acute P A O 2 = 77 mmHg). So the following may be employed for operational risk reduction: 1) develop procedures to increase P B as needed in the CEV, and use a gradual or staged reduction in cabin pressure during lunar outbound; 2) train crews for symptoms of hypoxia, to allow early recognition and consider pre-adaptation of crews to a hypoxic environment prior to launch, 3) consider prophylactic acetazolamide for acute pressure changes and be prepared to treat any AMS associated symptoms early with both carbonic anhydrase inhibitors and supplemental oxygen.
⎯ Better to prevent rather than treat DCS, or to constantly embolize the lung. ♦ Underlying Assumptions:
• Efficient and frequent EVAs drive the exploration initiative.
• Low pressure suit is always preferred to high pressure suit.
• There is an operational value to a short in-suit prebreathe.
• Vehicle atmosphere may not prevent risk of DCS during EVA. • Dedicated hyperbaric treatment capability may not be present.
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In-suit 30 40.0 (5.8) (2) References: Carson, et al. (1975) , McBarron, et al. (1993) , Waligora, et al. (1993) , NASA (2002) , NASA (2003) .
(1) 100% oxygen.
(2) In earlier versions of the Orlan suit, the pressure could be reduced to 26.5 kPa (3.8 psia) for short-duration work regime. References: Carson, et al. (1975 ), McBarron, et al. (1993 ), Waligora, et al. (1993 ), NASA (2002 ), NASA (2003 .
(2) In earlier versions of the Orlan suit, the pressure could be reduced to 26.5 kPa (3.8 psia) for short-duration work regime. PAO2 is computed acute alveolar oxygen partial pressure from alveolar oxygen equation.
Future Spacecraft Atmospheres
Note 1: Range of total pressure capability covers Earth launch, Earth entry, and contingencies. The Spectrum Of Hypoxia ♦ There is some confusion and overlap among the high altitude syndromes.
Summary of Recommendations for Constellation Mission Systems
♦ A sudden ascent to high altitude can result in a rapid death from Acute Hypoxia while a more gradual ascent to the same altitude can result in AMS or no symptoms at all.
♦ Symptoms of AMS generally take a longer period of time to develop (hrs-days) and there is great variability among the population of those who are susceptible.
♦ Severe and prolonged forms of AMS may lead to High Altitude Pulmonary Edema (HAPE) and High Altitude Cerebral Edema (HACE) and death.
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The Lake Louise AMS Scoring System ♦ Based on this committee's recommendations:
⎯ A diagnosis of AMS is based on a recent gain in altitude, at least several hours (>2) at the new altitude, and the presence of headache and at least one of the following symptoms: gastrointestinal upset, fatigue or weakness, dizziness or lightheadedness and difficulty sleeping.
♦ A score of three points or greater on the AMS Self-Report questionnaire alone or in combination with the clinical assessment score is diagnostic of AMS. The interviewers ratings of three signs:
Added to the self-report score (Roach 1993) 
Clinical Assessment
This system helped to standardize the diagnosis of AMS. ♦ Demonstrated, that the symptoms of AMS could be prevented or relieved by oxygen breathing and so "Proved" that it was the decrease in partial pressure of oxygen & subsequent hypoxia at high altitude, that caused AMS.
♦ This doctrine that hypoxia alone is the cause for AMS has held true for 150 years.
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Loepkky, Roach, Tucker, and others
But over the last thirty years, a new group of researchers have begun to question the conventional wisdom that the symptoms of AMS are solely due to hypoxia.
"the diminution of barometric pressure acts upon the living beings only by lowering the oxygen tension in the air, in the breath, and in the blood which supplies their tissues…. The increase in barometric pressure acts only by increasing oxygen tension in the air and blood…." Paul Bert, 1878. ♦ Consequently, maintaining sea level equivalent partial pressures of O 2 at any and all altitudes we "assume" no signs and symptoms of AMS should be seen. 22 Solid circles connected by the curve are studies done where HH was induced by ascent to altitude on air, but are HH exposures without simulated μG. The open boxes are exposures where μG adaptation through simulation or actual exposure is present as part of the HH. The two least stressful points along the curve at 6,000 and 7,000 feet are from Ge (2002) where he shows a slight increase in plasma EP concentration. The third point at 8,000 feet from Ge (2002) is within the open box from Waligora (1982) . ♦ NASA's past habitats and vehicles rarely exposed the astronaut to hypobaric and hypoxic conditions. ♦ Staged decompression protocols taking many hours to days with very high O 2 levels were used in the past. ♦ Likelihood of AMS almost nil.
♦ Specifies the development of human missions to Earth's moon, Mars and beyond. ♦ In order to accomplish this task NASA will be required to build an array of vehicles including interplanetary spacecraft, planetary landers, space suits, rovers and surface habitats.
♦ Due to the technical, financial and mission operational constraints, the most likely atmospheres of this constellation of habitats, vehicles, suits and rovers will likely be well below standard pressure (P B ).
♦ Future moon and mars missions with CEV, LSAM and lunar habitat amongst other issues will require efficient EVA egress with minimal prebreathe time while still avoiding DCS and venous gas emboli (VGE).
♦ This combination of hypobaria with a concomitant hypoxia simulates the conditions encountered by high altitude climbers.
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SO….. Are we putting future astronauts at an increased risk for AMS and all it's associated symptoms?
Incidence Of AMS
♦ The incidence of AMS as reported in the literature is highly variable. ♦ Most agree that some people may show mild AMS symptoms as low as 1,981-2,438m (6,500-8,000 ft). ♦ One report claims that as much as 25% of people may be affected with quick ascent to 1,891m, with 90% of symptoms resolving in 3 -4 days. ♦ Houston C.S. claims that 25-30% of people ascending to 3,048m (10,000 ft) will experience some type of AMS, this figure will double at 4,200m and almost all people will show some signs of AMS by 5,486m (18,000 ft). ♦ Roach et al 1998 that a small percentage, 5% of people who develop AMS at 3,962m (13,000 ft) will go on to develop life threatening HAPE and/or HACE.
♦ Based on extrapolation of current research it does not seem likely that one may experience severe AMS. ♦ The bigger issue is likely Performance. ♦ The bigger issue is a mitigation plan.
What Happens If Future Astronauts Develop AMS?
